HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Successful treatment of cytomegalovirus-induced hemophagocytic lymphohistiocytosis with ruxolitinib as a first-line treatment.

AuthorsGuangqiang Meng, Jingshi Wang, Yini Wang, Zhao Wang
JournalInfectious diseases now (Infect Dis Now) Vol. 51 Issue 3 Pg. 311-313 (May 2021) ISSN: 2666-9919 [Electronic] France
PMID33934812 (Publication Type: Case Reports, Letter)
Chemical References
  • Antiviral Agents
  • DNA, Viral
  • Immunologic Factors
  • Immunosuppressive Agents
  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • ruxolitinib
  • Ganciclovir
Topics
  • Aged
  • Antiviral Agents (therapeutic use)
  • Cytomegalovirus (isolation & purification)
  • Cytomegalovirus Infections (complications, diagnosis, drug therapy)
  • DNA, Viral (isolation & purification)
  • Female
  • Ganciclovir (therapeutic use)
  • Humans
  • Immunologic Factors (therapeutic use)
  • Immunosuppressive Agents (therapeutic use)
  • Lung Diseases, Interstitial (complications, drug therapy)
  • Lymphohistiocytosis, Hemophagocytic (diagnosis, drug therapy, virology)
  • Nitriles
  • Pyrazoles (therapeutic use)
  • Pyrimidines
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: